1228875-13-5

Usage

Uses

Used in Pharmaceutical Industry:
(4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to confer specific properties and functions to the final products. The presence of the fluorine atom can enhance the bioavailability, metabolic stability, and pharmacological activity of the resulting drugs.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, (4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine serves as a key building block for the creation of a wide range of organic compounds. Its unique structure allows for the development of new molecules with potential applications in various industries, such as materials science, agrochemicals, and specialty chemicals.
Used in Research and Development:
(4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine is utilized in research and development processes to explore its potential in creating new drugs or chemical substances. Its unique structure and properties make it an attractive candidate for the design and synthesis of novel compounds with improved therapeutic effects or innovative applications.
Overall, (4-fluorotetrahydro-2H-pyran-4-yl)MethanaMine is a valuable chemical intermediate with diverse applications across various industries, particularly in the pharmaceutical sector, where its unique structure and properties contribute to the development of innovative and effective products.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 883442-47-5 1,6-dioxaspiro[2.5]octane-2-carbonitrile 
• 1226507-95-4 2-(4-fluorotetrahydro-2H-pyran-4-yl)-2-hydroxyacetonitrile 
• 883442-46-4 (4-fluorotetrahydro-2H-pyran-4-yl) methanol 
• 1228875-11-3 (4-fluorotetrahydro-2H-pyran-4-yl)methyl methanesulfonate 
• 1454700-69-6 4-(azidomethyl)-4-fluorooxane 

Relevant academic research and scientific papers

CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR

A pro-apoptotic solid dispersion comprises, a Bcl -2 family protein inhibitory compound of Formula A as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula A, the water-soluble polymeric carrier, and the surfactant to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier, and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl -2 family proteins, for example cancer or an immune or autoimmune disease.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

INHIBITORS OF BETA-SECRETASE

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.

INHIBITORS OF BETA-SECRETASE

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACEl) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.